Is LL-37 safe?
Emerging ResearchSide effects, risks, and safety considerations based on available research.
Research status
LL-37 has some clinical data but research is still developing. Safety data exists but may come from small studies, short-term trials, or specific populations that may not reflect your situation.
Known concerns & side effects
- ⚠no FDA-approved therapeutic applications
- ⚠human clinical trials for exogenous administration are extremely limited
- ⚠injectable LL-37 from compounding pharmacies has variable quality and purity
- ⚠at high concentrations, LL-37 can be cytotoxic to human cells
- ⚠overexpression is associated with autoimmune conditions including psoriasis and rosacea
- ⚠claims about treating chronic infections like Lyme disease are not supported by clinical evidence
Use caution with
Relevant safety research
LL-37 antimicrobial activity and biofilm disruption in vitro
Finding: LL-37 demonstrated bactericidal activity against Staphylococcus aureus, Pseudomonas aeruginosa, and E. coli at micromolar concentrations. Also disrupted established biofilms of P. aeruginosa by 60-80%.
Limitation: In vitro concentrations required for biofilm disruption may not be achievable or safe in vivo. Serum proteins can bind and inactivate LL-37.
See all 2 studies on the full LL-37 profile.
Frequently asked questions
Can LL-37 treat Lyme disease?
There is no clinical evidence that exogenous LL-37 treats Lyme disease. While LL-37 shows antimicrobial activity in laboratory settings, in vitro activity against Borrelia does not translate to treating an established infection in humans. Lyme disease requires proper antibiotic treatment prescribed by a physician.
Is LL-37 the same as vitamin D's immune effect?
Vitamin D does upregulate LL-37 production in the body — this is one mechanism by which vitamin D supports immune function. However, taking exogenous LL-37 via injection is very different from the body producing it naturally via vitamin D signaling. The two are related but not equivalent approaches.
How is LL-37 administered?
In research and biohacking contexts, LL-37 is typically administered via subcutaneous injection. Oral administration would likely result in degradation by digestive enzymes. There is no established dosing protocol for humans as clinical trials are lacking.
Full LL-37 Profile
Evidence, timeline, products & more
Take the Peptide Quiz
Get personalized recommendations
Last updated: 2025-03-25
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.